These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37545091)

  • 1. Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1.
    van Vliet K; Dijkstra AM; Bouva MJ; van der Krogt J; Bijsterveld K; van der Sluijs F; de Sain-van der Velden MG; Koop K; Rossi A; Thomas JA; Patera CA; Kiewiet MBG; Waters PJ; Cyr D; ; Boelen A; van Spronsen FJ; Heiner-Fokkema MR
    J Inherit Metab Dis; 2023 Nov; 46(6):1104-1113. PubMed ID: 37545091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Cases of Maleylacetoacetate Isomerase Deficiency with Detection by Newborn Screening and Natural History over 32 Years: Experience from a German Newborn Screening Center.
    Gramer G; Wortmann SB; Fang-Hoffmann J; Kohlmüller D; Okun JG; Prokisch H; Meitinger T; Hoffmann GF
    Int J Neonatal Screen; 2024 Feb; 10(1):. PubMed ID: 38535121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
    De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
    Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A False-Negative Newborn Screen for Tyrosinemia Type 1-Need for Re-Evaluation of Newborn Screening with Succinylacetone.
    Dijkstra AM; Evers-van Vliet K; Heiner-Fokkema MR; Bodewes FAJA; Bos DK; Zsiros J; van Aerde KJ; Koop K; van Spronsen FJ; Lubout CMA
    Int J Neonatal Screen; 2023 Dec; 9(4):. PubMed ID: 38132825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
    Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
    Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency.
    Yang H; Al-Hertani W; Cyr D; Laframboise R; Parizeault G; Wang SP; Rossignol F; Berthier MT; Giguère Y; Waters PJ; Mitchell GA;
    J Med Genet; 2017 Apr; 54(4):241-247. PubMed ID: 27876694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
    Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
    Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update.
    Giguère Y; Berthier MT
    Adv Exp Med Biol; 2017; 959():139-146. PubMed ID: 28755192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots.
    Allard P; Grenier A; Korson MS; Zytkovicz TH
    Clin Biochem; 2004 Nov; 37(11):1010-5. PubMed ID: 15498530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
    Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
    Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosinemia type 1: an overview of nursing care.
    Barnby E
    Pediatr Nurs; 2014; 40(2):61-8, 90. PubMed ID: 24941508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program.
    Zytkovicz TH; Sahai I; Rush A; Odewale A; Johnson D; Fitzgerald E; Britton D; Eaton RB
    Clin Biochem; 2013 May; 46(7-8):681-4. PubMed ID: 23462696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
    Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
    Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening for hereditary tyrosinemia and genotype analysis in newborns].
    Tong F; Yang R; Liu C; Wu D; Zhang T; Huang X; Hong F; Qian G; Huang X; Zhou X; Shu Q; Zhao Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 48(4):459-464. PubMed ID: 31901053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening.
    Priestley JRC; Alharbi H; Callahan KP; Guzman H; Payan-Walters I; Smith L; Ficicioglu C; Ganetzky RD; Ahrens-Nicklas RC
    Int J Neonatal Screen; 2020 Jun; 6(2):. PubMed ID: 32832707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a fungal maleylacetoacetate isomerase gene and identification of its human homologue.
    Fernández-Cañón JM; Peñalva MA
    J Biol Chem; 1998 Jan; 273(1):329-37. PubMed ID: 9417084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosinemia type I: a clinico-laboratory case report.
    Karnik D; Thomas N; Eapen CE; Jana AK; Oommen A
    Indian J Pediatr; 2004 Oct; 71(10):929-32. PubMed ID: 15531838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.
    Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC
    Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
    la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
    Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.